THERAPY DOSSIER · th-4aaa264ff28a

Cell-penetrating peptide-BH4 conjugates (Tat-BH4, Pip2b-BH4)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21839124 ↗2011Reported benefit

Systemic delivery of BH4 anti-apoptotic peptide using CPPs prevents cardiac ischemia-reperfusion injuries in vivo.

MouseIschaemia-reperfusionCardiacC57BLIntravenous1 mg/kg5 min before reperfusion

Model: Myocardial ischaemia-reperfusion injury

A single low dose of CPP-BH4 peptide reduced infarct size by about 47% and apoptosis by about 60% after cardiac ischaemia-reperfusion.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…